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Identification and manipulation 
of the pleuromutilin gene cluster 
from Clitopilus passeckerianus 
for increased rapid antibiotic 
production
Andy M. Bailey1, Fabrizio Alberti1, Sreedhar Kilaru1, Catherine M. Collins1, Kate de  
Mattos-Shipley1, Amanda J. Hartley1, Patrick Hayes1, Alison Griffin2, Colin M. Lazarus1, 
Russell J. Cox3, Christine L. Willis3, Karen O’Dwyer4, David W. Spence3 & Gary D. Foster1
Semi-synthetic derivatives of the tricyclic diterpene antibiotic pleuromutilin from the basidiomycete 
Clitopilus passeckerianus are important in combatting bacterial infections in human and veterinary 
medicine. These compounds belong to the only new class of antibiotics for human applications, 
with novel mode of action and lack of cross-resistance, representing a class with great potential. 
Basidiomycete fungi, being dikaryotic, are not generally amenable to strain improvement. We report 
identification of the seven-gene pleuromutilin gene cluster and verify that using various targeted 
approaches aimed at increasing antibiotic production in C. passeckerianus, no improvement in yield 
was achieved. The seven-gene pleuromutilin cluster was reconstructed within Aspergillus oryzae giving 
production of pleuromutilin in an ascomycete, with a significant increase (2106%) in production. This is 
the first gene cluster from a basidiomycete to be successfully expressed in an ascomycete, and paves 
the way for the exploitation of a metabolically rich but traditionally overlooked group of fungi.
Antimicrobial resistance is now universally considered to be one of the greatest threats to human health. 
Continually emerging resistance has been confounded by a lack of investment into antibiotic research and devel-
opment over recent decades. The World Health Organization’s (WHO) 2014 report on global surveillance of anti-
microbial resistance has recently warned that without urgent, coordinated action, the world is heading towards a 
post-antibiotic era, in which common infections and minor injuries, which have been treatable for decades, may 
again be fatal.
A highly promising class of antibiotics for human therapeutics are the semi-synthetic pleuromutilin antibi-
otics. Pleuromutilin is a tricyclic diterpene produced by the basidiomycete Clitopilus passeckerianus and related 
basidiomycete fungi1, which was initially isolated and characterized by Kavanagh and co-workers in 19512. The 
pleuromutilin derivatives tiamulin and valnemulin have been used in veterinary medicine for many years3, but an 
increasing need for new antibiotics has led to a surge in the development of pleuromutilin derivatives specifically 
for human use.
In 2007, retapamulin became the first semi-synthetic pleuromutilin antibiotic to be approved by the FDA and 
EMA and is recommended for the treatment of impetigo and infected small lacerations, abrasions and sutured 
wounds4. This represents the first antibiotic of a new class to be approved for use against topical infections in more 
than 30 years.
Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilin antibiotics, has 
been developing novel pleuromutilin derivatives with potent and broad-spectrum activities and the desired 
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pharmacokinetic characteristics for oral and intravenous (IV) administration. One derivative in particular, 
BC-3781 (lefamulin), is particularly promising and has recently been granted Qualified Infectious Disease 
Product (QIDP) as well as Fast Track status designation, for the treatment of community-acquired bacterial pneu-
monia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Lefamulin is soon to enter phase 
III clinical trials for the treatment of CABP, and also holds great potential as a treatment for hospital-acquired 
and ventilator-associated bacterial pneumonia (HABP/VABP), as well as ABSSSI, with potential in several 
other indications (such as sexually transmitted infections, including multidrug-resistant MDR gonorrhea and 
osteomyelitis).
There has also been increasing interest in pleuromutilin antibiotics as potential agents to treat multi-drug 
resistant (MDR-) and extensively drug resistant (XDR-) tuberculosis strains, which are increasingly difficult to 
treat5,6. Although the biochemical properties and mode of action of pleuromutilins are well understood7–10, and a 
partial chemical elucidation of the potential pathway has previously been proposed11, the complete biosynthesis 
of this increasingly important natural product has never been elucidated. As with most natural products, and 
particularly fungal natural products, the yields in the native host are very low, and the process of fermentation 
and isolation of the desired compounds can be logistically challenging. This is particularly true for basidiomy-
cete fungi such as Clitopilus passeckerianus, where traditional strain improvement techniques such as random 
mutagenesis are rarely successful due to their dikaryotic nature. For these reasons, understanding the biosynthetic 
pathway of a natural product is often key to developing a strain which can be exploited successfully.
In this work we set out to identify the pleuromutilin gene cluster and identify a strain improvement approach. 
Initial attempts to improve pleuromutilin yields in C. passeckerianus were followed by the reconstruction of the 
biosynthetic pathway in the heterologous host Aspergillus oryzae. This represents the first cross-phylum heter-
ologous expression of a basidiomycete gene cluster in an ascomycete host, so will not only increase the potential 
of the pleuromutilin antibiotics but may also help to inform the future discovery and exploitation of secondary 
metabolites from the rich but underexploited basidiomycete fungi.
Results
Identification of the candidate pleuromutilin gene cluster. In fungi, it is usual for the gene clusters 
encoding enzymes for diterpene biosynthesis to include a cluster-specific geranylgeranyl pyrophosphate syn-
thetase (GGS). On this assumption, we used PCR with degenerate primers ggs27 and ggs29 to isolate GGS-related 
products from the genome of C. passeckerianus. Amplification products were cloned and sequenced. After taking 
into account allelic differences due to the dikaryotic nature of the fungus, four different GGS-related sequences 
were obtained and these were screened to determine which followed the predicted expression patterns for pleu-
romutilin production by RT-PCR and Northern analysis. RT-PCR excluded ggs-1, whilst Northern analysis showed 
that only ggs-2 was highly expressed under pleuromutilin-producing conditions (Supplementary Figure 1). 
Southern blot analysis determined that ggs-2 is only present once in the genome (Supplementary Figure 2A).
Probing a C. passeckerianus genomic library with this partial ggs-2 PCR product identified lambda clone λ G4, 
and sequencing the full 8.4 kb insert revealed a full-length ggs gene of 1291 bp (Pl-ggs), containing 4 putative 
introns and encoding a 350 amino-acid protein. Upstream of Pl-ggs was a partial diterpene cyclase (cyc) gene, 
named Pl-cyc; downstream was a full length cytochrome P450 gene (Pl-p450-1) and a second partial cytochrome 
P450 gene (Pl-p450-2), showing that Pl-ggs was located within a likely diterpene gene cluster. Rescreening the 
library to isolate contiguous sequences identified λ C34, in which an overlapping region shared 100% homology 
with λ G4, and λ P5, whose overlap with λ G4 contained several SNPs and indels. This indicated that λ G4 and 
λ C34 originate from the same allelic version of the pleuromutilin gene cluster, while λ P5 is derived from the 
other allele. In total a genomic region of 34.6 kb was sequenced and 13 likely genes were identified (Fig. 1 and 
Table 1).
Whilst Pl-ggs and Pl-cyc could be inferred as the core genes of the diterpene synthesis, from bioinformatic 
analysis alone, it was not possible to confidently predict the boundaries of the gene cluster. We therefore analysed 
gene expression by northern blotting to identify which genes were coordinately expressed and correlated with 
conditions known to induce pleuromutilin biosynthesis.
Genes for GGS, cyclase, acetyl transferase (ATF), short-chain dehydrogenase/reductase (SDR) and three 
P450 s were shown to be upregulated during pleuromutilin production, whereas flavin binding monooxygenase 
(fbm), zinc binding dehydrogenase (zbdh), and aminotransferase genes were not, suggesting that they lie outside 
the pleuromutilin gene cluster (Supplementary Figure 3).
A more thorough expression analysis, combining quantitative RT-PCR with an analysis of pleuromutilin 
production, demonstrated that the seven putative pleuromutilin biosynthetic genes are not only highly differ-
entially expressed under production and non-production conditions, but also tightly co-regulated (Fig. 2). See 
Supplementary Figure 4 for the corresponding time-course of pleuromutilin yields.
Figure 1. The pleuromutilin gene cluster of C. passeckerianus. Genes involved in the biosynthesis of 
pleuromutilin are light grey. Those in dark grey are considered to lie outside the gene cluster. The horizontal 
lines above show the regions of the cluster contained within the three lambda phage clones λ C34, λ G4 and λ P5.
www.nature.com/scientificreports/
3Scientific RepoRts | 6:25202 | DOI: 10.1038/srep25202
The gene for farnesyl diphosphate synthase (fds) was also isolated and sequenced to assess any role in the 
pathway. This is another key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphos-
phate, a precursor for several classes of essential metabolites. Degenerate primers (fdsf2A and fdsr4) were used 
to amplify an fds gene fragment, which was used to pull out a lambda clone that was sequenced in its entirety 
(Supplementary Figure 5). Southern blot analysis demonstrated that this fds is only present once in the genome, 
at a different locus to the pleuromutilin cluster, suggesting that it is responsible for the biosynthesis of farnesyl 
diphosphate for both primary and secondary metabolism. Genes encoding β -tubulin and α - actin were also iso-
lated from a genomic library as reported in Kilaru et al.12, allowing their promoter elements to be exploited for 
use in expression cassettes.
A gene-silencing approach was used to directly link the 7-gene cluster with pleuromutilin production, where the 
two core genes Pl-ggs and Pl-cyc were silenced. Plasmids based on pYES-hph-cbxgene (Supplementary Figure 6) 
were generated containing the full length coding regions of Pl-ggs and Pl-cyc in the antisense direction, under 
the control of the Agaricus bisporus gpdII promoter. Silencing using antisense constructs has previously been 
demonstrated to be an efficient approach to genetic manipulation in C. passeckerianus12. Initial screening of trans-
formants via plate-based bioassay revealed reduced clearing zones for both genes (Supplementary Figures 7 to 9), 
providing direct evidence for their involvement in pleuromutilin production. Further analysis of selected trans-
formants by HPLC demonstrated reduction in pleuromutilin titres. For example the yield of pleuromutilin was 
reduced by 87% to 103 μ g/g in transformant p004-GGSantigene-16, compared to the wild-type C. passeckerianus 
yield of 765 μ g/g.
Attempted increase in pleuromutilin production in C. passeckerianus. Overexpression of the puta-
tive pleuromutilin biosynthetic genes was attempted in C. passeckerianus. Initially, the native promoters were used 
to drive expression. Eight expression vectors were constructed (Supplementary Figure 6B), containing the genes 
Pl-p450-3, Pl-atf, Pl-cyc, Pl-ggs, Pl-p450-1, Pl-p450-2, Pl-sdr, and Cp-fbm, and transformed into C. passeckeri-
anus (Table 2). At least fifty transformants for each gene were screened via plate-based bioassay with Bacillus 
subtilis but no set of transformants showed any significant increase in clearing zone compared to untransformed 
C. passeckerianus (Supplementary Figures 10 to 17). Unexpectedly, however, every set of transformants contained 
some strains which exhibited a significant reduction of clearing zone, with some transformants expressing Pl-ggs, 
Gene
Length 
(bp)
Number 
of introns
Predicted protein 
length (aa) Putative function
Closest known homologue and 
accession number
FDS Locus
Cp-fds 1487 5 375 Farnesyl diphosphate synthase (FDS) FPPS from Lactarius chrysorrheus (BAD15361)
Cp-cdb 3436 21 764 Cellobiose dehydrogenase cbd from Coniophora puteana (BAD32781)
Cp-ATPase 4549 14 1225 Cation transporter Cation transporting ATPase from Aspergillus fumigatus Af293 (XP_754245)
Cp-ccp 435 0 144 Cerato-platanin protein cerato-platanin 6 from Crinipellis campanella (AGL40521)
Pleuromutilin Locus
Pl-p450-3 2108 10 522 Cytochrome P450 Pleurotus sapidus putative Cytochrome P450 monooxygenase (CAJ00405)
Pl-atf 1304 3 377 Acetyltransferase
Aspergillus fumigatus Acetyltransferase 
TRI7-like toxin biosynthesis protein 
(XP_746970)
Pl-cyc 3040 3 959 Terpene Cyclase
Gibberella fujikuroi Ent-kaurene synthase 
(Ent-copalyl diphosphate synthase) 
(Q9UVY5)
Pl-ggs 1291 4 350 Geranylgeranyl pyrophosphate synthetase (GGS)
Mucor racemosus Geranylgeranyl 
pyrophosphate synthetase (Q9P885)
Pl-p450-1 2286 13 523 P450 monooxygenase Pleurotus sapidus cytochrome P450-3 monooxygenase (CAL69751)
Pl-p450-2 2124 11 525 P450 monooxygenase Pleurotus sapidus cytochrome P450-3 monooxygenase (CAL69751)
Pl-sdr 945 3 254 Short-chain dehydrogenase/reductase (SDR)
Desulfitobacterium hafniense DCB-2 
short-chain dehydrogenase/reductase 
SDR (ZP_01373200)
Cp-zbdh 1479 10 321 Oxidoreductase
Neosartorya fischeri NRRL 181 
oxidoreductase, zinc-binding 
dehydrogenase family (XP_001264189)
Cp-fbm 2434 11 616 Monooxygenase
Aspergillus fumigatus Af293 flavin-
binding monooxygenase-like protein 
(XP_751903)
Cp-pp1 2144 21 338 Unknown Predicted protein from Laccaria bicolor S238N-H82 (XP_001884957)
Cp-pp2 – – – Unknown predicted protein from Coprinopsis cinerea (EAU81003).
Cp-at 
(partial) – – – Putative aminotransferase
Moniliophthora roreri aminotransferase 
family protein (XP_007868896)
Table 1. Genes sequenced during this project.
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Pl-cyc or Pl-p450-1 showing a complete disappearance of antibacterial activity. In particular, overexpression of 
Pl-cyc from its native promoter generated a range of transformants with greatly reduced or complete absence 
of clearing zones (Supplementary Figure 11). An HPLC analysis of pYES-hph-nativeCycgene transformants 2, 
12, 23 and 43 showed a reduction in pleuromutilin titres of 38, 75, 98 and 89% respectively (436, 177, 11 and 
78 μ g/g) when compared to wild type C. passeckerianus (703 μ g/g). This suggests that a form of sense suppression 
is occurred in these transformants.
As overexpression using native promoters did not enhance pleuromutilin production, the constitutive strong 
promoter gpdII from A. bisporus was instead used to drive expression of six genes in C. passeckerianus. Twelve 
constructs were made to include the individual genes Cp-fds, Pl-ggs, Pl-cyc, Pl-p450-1, Pl-p450-2, and Pl-p450-3, 
either with or without an additional intron (64 bp intron-exon region of A. bisporus gpdII) at the 5′ end of the gene 
(Supplementary Figure 6C). The presence of a 5′ intron has previously been shown to be essential for successful 
green fluorescent protein (gfp) and phleomycin resistance (ble) gene expression in C. passeckerianus12. At least 
twenty transformants were generated for each group using the 12 expression vectors (Table 3). Transformants 
overexpressing the Cp-fds or Pl-ggs were screened using HPLC for improved pleuromutilin titres. The majority 
of transformants demonstrated no significant increase in antibiotic titres, but one strain expressing the Pl-ggs 
without the additional intron showed a 50% increase in pleuromutilin yields when compared to wild-type 
C. passeckerianus (Table 2 and Supplementary Figure 18). Northern blot analysis showed increased levels of Pl-ggs 
transcripts when compared to the wild-type (Supplementary Figure 19), suggesting that the improved titre is due 
to increased GGS expression. The strains overexpressing Pl-cyc, Pl-p450-1, Pl-p450-2, or Pl-p450-3 were screened 
via plate-based bioassay against B. subtilis, but no significant increases in clearing zones were observed (Table 3 
and Supplementary Figures 20 to 26). A reduction in clearing zone diameter was again observed for some trans-
formants from every group, and a complete loss of observable inhibition was seen for one transformant express-
ing the Cyclase gene without the additional intron (Supplementary Figure 20).
As a final approach to increase pleuromutilin titres in the native host, the entire putative gene cluster for 
pleuromutilin – comprising the nine genes Pl-p450-3, Pl-atf, Pl-cyc, Pl-ggs, Pl-p450-1, Pl-p450-2, Pl-sdr, Cp-zbdh 
and Cp-fbm – was cloned into a yeast shuttle vector (pYES2-hph-pleurocluster – Supplementary Figure 6D), and 
transformed into C. passeckerianus. One hundred and nineteen transformants were screened for increased anti-
biotic production by plate-based bioassay. Sixteen transformants showed a 20 to 40% increase in clearing zone 
diameter, but seven transformants showed complete disappearance of clearing zone (Supplementary Figures 27 
and 28).
Heterologous production of pleuromutilin in A. oryzae. We heterologously expressed the seven genes 
of the putative gene cluster (Pl-p450-3, Pl-atf, Pl-cyc, Pl-ggs, Pl-p450-1, Pl-p450-2, Pl-sdr) in A. oryzae NSAR1, 
using our established Aspergillus oryzae multi-gene expression system13. Each of the genes were amplified from 
cDNA and placed under the control of A. oryzae promoters (Fig. 3A). Twelve independent transformants were 
screened for their ability to inhibit B. subtilis growth via plate-based bioassay. Eleven strains showed production 
and diffusion of an antibacterial compound in the medium, witnessed by appearance of clearing zone around the 
mycelia (Fig. 3B; Supplementary Figure 29). Only one strain (NSAR1 7 TR49) did not inhibit bacterial growth. 
RT-PCR demonstrated that three out of the seven transgenes were not being expressed in this strain (Pl-p450-1, 
Pl-p450-2 and Pl-p450-3). Expression of all seven transgenes was confirmed for all of the other transformants 
(Supplementary Figure 30). To confirm pleuromutilin production, fermentation cultures were extracted with 
ethyl acetate, and the resulting crude extracts were analysed by HPLC-MS. As expected no production of new 
metabolites was detected from strain NSAR1 7 TR49, whereas two new compounds (1 and 2) were detected 
from all other strains (Fig. 4A), with 1 showing the same retention time and mass/charge ratio (m/z) as authen-
tic pleuromutilin. 1 and 2 were purified from a 1 L culture via preparative-HPLC (yielding 12.4 mg and 7.5 mg 
respectively), and characterized by NMR spectroscopy and ESIHRMS. 1 was determined to be pleuromutilin, 
by ESIHRMS and by a comparison of the 1H-NMR and 13C-NMR data with that of authentic pleuromutilin and 
data in the literature14 (Supplementary Figures 31 to 34; Supplementary Table 2). ESIHRMS and a full-range of 
NMR analyses – including 2D-COSY, HMBC, and HSQC – allowed the identification of 2 as 14-O-acetyl-mutilin 
(Supplementary Figures 35 to 39; Supplementary Table 3), which is another known product of fermentation of 
C. passeckerianus15. It has not previously been proven to a precursor of pleuromutilin.
Pleuromutilin yields were quantified for the A. oryzae transformants showing the highest production of 
1 from the analytical HPLC-MS, and a 195 to 1,053% increase over the native producer was observed, with a 
maximum production of 84.24 mg/l for NSAR1 7 TR51 (Fig. 4B). Taking into account that C. passeckerianus 
requires a preliminary seed culture prior to fermentation, the time between initial culture inoculation and har-
vesting of the antibiotic is also halved in A. oryzae compared to C. passeckerianus (Fig. 4B). This brings the 
increase in pleuromutilin production in A. oryzae to 2,106% over C. passeckerianus. We also estimated the titre 
of 14-O-acetyl-mutilin 2, produced by the three A. oryzae transformants. Strain NSAR1 7 TR27 produced the 
highest titre of 74.52 mg/l, strain NSAR1 7 TR52 produced 18.33 mg/l, whereas no detectable amounts of 2 were 
observed in NSAR1 7 TR51, the highest producer of pleuromutilin 1 (Fig. 4B).
We carried out Southern blot analysis to detect copy number of the transgenes in these three same trans-
formant strains and detected the presence of multiple copies of the genes Pl-atf and Pl-sdr in the highest pro-
ducing strain NSAR1 7 TR51 (Supplementary Table 4). Multiple copies of the genes for the three cytochrome 
P450 s were found in strain NSAR1 7 TR52 (titre of 1: 15.67 mg/l). This does not appear to provide any further 
increase in antibiotic titre compared to strain NSAR1 7 TR27 (titre of 1: 21.86 mg/l) which has a single copy for 
each transgene.
www.nature.com/scientificreports/
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Discussion
The emergence of antibiotic resistance is posing a major concern for human health, and the development of 
robust alternatives to the currently-exploited antimicrobial agents has therefore become of primary importance. 
As the newest class of antibiotics for use in human therapeutics, and a class with great potential to treat var-
ious resistant and highly virulent pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA) and 
Multi-Drug Resistant (MDR)-tuberculosis, the pleuromutilin antibiotics are becoming increasingly important. 
Nevertheless, the genetic basis of pleuromutilin production has not before been elucidated. For this reason we 
set out to identify the pleuromutilin gene cluster in C. passeckerianus, which is currently used to commercially 
produce pleuromutilin – and investigate potential approaches to increase pleuromutilin yields.
We hypothesized that, pleuromutilin being a diterpene compound, a pleuromutilin gene cluster may contain a 
pathway specific geranylgeranyl diphosphate synthase gene (ggs), as is the case for many characterized fungal dit-
erpene gene clusters16–18. By screening a λ -phage genomic DNA library of C. passeckerianus we isolated four ggs 
genes. Of these four genes, only ggs-2 was novel, the other three having been previously cloned and sequenced19. 
ggs-2 was also the only ggs shown to be highly expressed under pleuromutilin production conditions, and was 
shown to be present only once in the genome, making it highly likely that this was the ggs responsible for provid-
ing geranyl-geranyl diphosphate (GGPP) for the biosynthesis of pleuromutilin and referred to thereafter as Pl-ggs.
Figure 2. Real-time PCR data for the seven pleuromutilin biosynthesis genes from C. passeckerianus when 
grown in production (CGC) and non-production (MM) media. β-tubulin was used as a reference gene and 
non-production media on day 3 was used as the calibrator sample (all other expression is shown relative to this 
data point).
Gene 
Expressed Plasmid
Total 
transformants
Transformants 
assayed
Clearing zone diameter 
range (% of wild-type)
Average clearing zone 
diameter (% of wild-type)
p450-3 pYES-hph-nativep450-3gene 221 50 80–113% 98.4%
atf pYES-hph-nativeATFgene 188 50 76–122% 106.0%
cyc pYES-hph-nativeCycgene 189 56 0–128% 96.9%
ggs pYES-hph-nativeGGSgene 179 45 0–121% 102.8%
p450-1 pYES-hph-nativep450-1gene 167 56 0–142% 111.1%
p450-2 pYES-hph-nativep450-2gene 156 53 60–122% 104.2%
sdr pYES-hph-nativeSDRgene 98 50 84–112% 98%
fbm pYES-hph-nativeFBMgene 138 52 80–113% 98.4%
Table 2. Transformants obtained with vectors containing pleuromutilin pathway genes under the 
control of their native promoters. A number of each set were analysed by bioassay to estimate pleuromutilin 
production. The range and average clearing zone diameters are shown as a percentage of wild-type C. 
passeckerianus.
www.nature.com/scientificreports/
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Genome walking and sequencing of other λ -phage clones allowed the identification of genes adjacent to Pl-ggs 
with potential roles in secondary metabolite biosynthesis. These included a gene encoding a cyclase (Pl-cyc), 
which commonly catalyzes the cyclization of GGPP to give the first cyclic intermediate found in the biosynthesis 
of diterpenes, as well as genes encoding an acetyl transferase (Pl-atf), a short-chain dehydrogenase/reductase 
(Pl-sdr), three cytochrome P450s (Pl-p450-1, Pl-p450-2 and Pl- p450-3), a zinc-binding dehydrogenase (Cp-zbdh), 
a flavin-binding monooxygenase-like protein (Cp-fbm), and four other putative proteins (Cp-pp1, Cp-pp2, Cp-at 
and Cp-epl1). Differential expression of the putative pleuromutilin gene cluster (Pl-ggs, Pl-cyc, Pl-atf, Pl-sdr, 
Pl-p450-1, Pl-p450-2 and Pl-p450-3), under pleuromutilin production and non-production conditions was 
assessed through Northern blot analysis. Quantitative PCR analysis confirmed that these seven genes had high 
expression under production conditions of pleuromutilin, as well as being tightly co-regulated. This allowed the 
borders of the putative gene cluster to be defined.
By employing the molecular tools that we previously developed for genetic manipulation of C. passeckeri-
anus12, we attempted to increase antibiotic production titres through overexpression of genes from the putative 
pleuromutilin gene cluster. Lines of the fungus with additional copies of each of the genes Pl-ggs, Pl-cyc, Pl-atf, 
Pl-sdr, Pl-p450-1, Pl-p450-2, Pl-p450-3 and Cp-fbm under control of their native promoter sequence, were gen-
erated. Rather than leading to an increase in pleuromutilin titres, in multiple transformed strains, there was 
a reduction or loss of pleuromutilin production. This points to C. passeckerianus having a ‘sense-suppression’ 
mechanism, whereby the introduction of an exogenous copy of a gene will silence both the exogenous and endog-
enous copies. Such a phenomenon has been seen in other basidiomycete fungi such as Cryptococcus neoformans20 
and Schizophyllum commune21.
Gene 
Expressed Plasmid
Total 
transformants
Pleuromutilin titre 
range (μg/g)
Clearing zone range (and average) as 
a percentage of wild-type
FDS p004-CP1-FDSgene 55 595–810 –
FDS p004-CP1-iFDSgene 20 600–920 –
GGS p004-CP1-GGSgene 32 495–1,010 –
GGS p004-CP1-iGGSgene 22 605–795 –
Cyclase pYES-hph-Cycgene 31 – 0–109.4% (89.0%)
Cyclase pYES-hph-iCycgene 23 – 100.8–122.0% (106.7%)
P450-1 pYES-hph-p450-1gene 20 – 70.4–103.0% (92.4%)
P450-1 pYES-hph-ip450-1gene 23 – 77.0–103.7% (92.5%)
P450-2 pYES-hph- p450-2gene 22 – 68.1–107.3% (89.3%)
P450-2 pYES-hph-ip450-2gene 30 – 83.7–105.2% (94.2%)
P450-3 pYES-hph-ip450-3gene 32 – 49.7–113.8% (98.3%)
Table 3. Total number of transformants obtained with vectors containing pleuromutilin pathway genes 
under the control of A. bisporus gpdII promoter. The FDS and GGS lines were analysed by HPLC. All others 
were analysed by bioassay. The titres of pleuromutilin recorded through HPLC (μ g of pleuromutilin per g of dry 
mycelial mass) are reported for the transformant lines overexpressing the genes fds and ggs. The wild-type levels 
were 690–815 μ g/g.
Figure 3. (A) Plasmid maps of vectors pTYGSargGGSCYC, pTYGSadeP450s, pTYGSbarATFSDR. The features 
for replication and selection in E. coli and S. cerevisiae are common to the three vectors, therefore shown only in 
pTYGSargGGSCYC. (B) Plate-based bioassay showing clearing zones produced by (i) A. oryzae NSAR1 7 TR15, 
(ii) A. oryzae NSAR1 7 TR35, (iii) A. oryzae NSAR1 7 TR42, (iv) A. oryzae NSAR1 7 TR51, (v) C. passeckerianus 
CP1, and (vi) untransformed A. oryzae NSAR1.
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Overexpression of six selected genes (Cp-fds, Pl-ggs, Pl-cyc, Pl-p450-1, Pl-p450-2 and Pl-p450-3) was also 
attempted by placing them under the control of the gpdII promoter of Agaricus bisporus, which is known to drive 
strong expression in C. passeckerianus12. Although not present in the pleuromutilin gene cluster, the farnesyl 
diphosphate synthase gene (Cp-fds) was included within this set as increasing substrate availability to a pathway 
can increase production. Only one strain overexpressing Pl-ggs showed approximately 50% increase in pleu-
romutilin titre, whereas all other strains showed either no change in pleuromutilin production, or a reduction 
in titres. The whole genomic region containing the putative cluster was also cloned and introduced in additional 
copies to the genome of C. passeckerianus, but this also failed to provide a consistent and reproducible significant 
increase in antibiotic production.
Since the manipulation of the pleuromutilin gene cluster in the native host did not achieve a robust increase 
in antibiotic titre, total biosynthesis of pleuromutilin was recreated in a secondary host, with the aim of providing 
an alternative platform for improved production of the antibiotic. The ascomycete fungus Aspergillus oryzae was 
used for this purpose, as it has been used before as recipient organism for total biosynthesis of other fungal SMs, 
such as the diterpene aphidicolin22 and the polyketide tenellin23. The cDNA sequences of the seven genes iden-
tified as constituting the gene cluster in C. passeckerianus – Pl-ggs, Pl-cyc, Pl-atf, Pl-sdr, Pl-p450-1, Pl-p450-2 and 
Pl-p450-3 – were cloned and placed under control of constitutive promoters for expression in A. oryzae, using a 
modified version of the expression vectors designed by Pahirulzaman, Williams and Lazarus12. De novo produc-
tion of pleuromutilin in A. oryzae transformants was assessed via plate-based bioassay, as well as purification and 
Figure 4. (A) De novo production of pleuromutilin (1) and 14-O-acetyl-mutilin (2) in A. oryzae. HPLC 
traces of untransformed A. oryzae NSAR1 (i), A. oryzae with GGS, Cyclase, P450-1, P450-2, P450-3, ATF, and 
SDR from C. passeckerianus (ii), and authentic pleuromutilin (iii). All traces were monitored through ELSD 
(Evaporative Light Scattering Detector). (B) Pleuromutilin and 14-O-acetyl-mutilin titres from A. oryzae 
transformant strains and C. passeckerianus. The titres are expressed either as mg of compound produced per 
litre of fungal culture (mg/l) or as mg of compound produced per gram of dry mass of mycelium (mg/g). C. 
passeckerianus required a total of 10 days between inoculation and harvesting, due to the need for a 5-day seed 
culture in PVS, followed by another 5-day production culture in CGC. A. oryzae transformants were only grown 
for 5 days in production culture CMP, which was inoculated directly from plates.
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consequent NMR characterization of novel compounds. The metabolite 14-O-acetyl-mutilin, described in litera-
ture as a side-product from fermentation of pleuromutilin-producing fungi14, could also be isolated from the same 
strains. Quantification of pleuromutilin demonstrated that the A. oryzae transformants were producing higher 
pleuromutilin titres than C. passeckerianus, with one strain giving a remarkable 10-fold increase, which increases 
to 20-fold if the total fermentation time required is taken into account. Moreover, further improvement of the 
pleuromutilin-producing A. oryzae strain can now be achieved through classical means of random mutagenesis 
in a well understood host, as well as by promoting conversion of the putative precursor 14-O-acetyl-mutilin into 
pleuromutilin. Notably, among the pleuromutilin-producing A. oryzae strains tested, the strain that showed high-
est production of pleuromutilin also exhibited no detectable amounts of 14-O-acetyl-mutilin, whereas one strain 
with lower pleuromutilin production showed higher amounts of 14-O-acetyl-mutilin. A higher rate of conversion 
from 14-O-acetyl-mutilin to pleuromutilin could be achieved through improved expression of the gene respon-
sible for catalyzing the putative last step of the pathway. The use of a well-known host such as A. oryzae, which 
produces few other secondary metabolites will also increase the efficiency of downstream purification.
The work described here has identified and defined the gene cluster for the important diterpene antibiotic 
pleuromutilin, from the basidiomycete fungus C. passeckerianus. The lack of consistent enhancement in antibiotic 
titre obtained through overexpression of the gene cluster in the native host suggests that, despite the availability 
of molecular tools, C. passeckerianus is not amenable to genetic manipulation aimed at improving metabolite 
production. Ultimately, seven clustered genes – Pl-ggs, Pl-cyc, Pl-atf, Pl-sdr, Pl-p450-1, Pl-p450-2 and Pl-p450-3 
– were identified and confirmed to be sufficient to ensure biosynthesis of pleuromutilin, as shown by de novo pro-
duction of the antibiotic through heterologous expression in A. oryzae. This also established a potential alterna-
tive method for production of the antibiotic in high titres, which will be needed to support large-scale production 
of pleuromutilin as novel semi-systemic pleuromutilin derivatives are launched.
Beyond the importance of this work to the field of pleuromutilin research, this also represents the first suc-
cessful heterologous expression of an entire basidiomycete secondary metabolite gene cluster in a well-known 
ascomycete host. This demonstrates the potential value of this approach for producing natural products from 
the under exploited and often intractable basidiomycete fungi, in titres which are suitable for commercial 
exploitation.
Materials and Methods
Bacterial and yeast strains. The Escherichia coli strains routinely used for this study, JM109 and KW251 
(both Promega, Southampton, UK), were grown on Luria-Bertani (LB) agar plates, supplemented when neces-
sary with either ampicillin (100 μ g/ml) or tetracycline (15 μ g/ml). Bacillus subtilis was grown on Tryptic Soy Agar 
(TSA). E. coli One Shot® ccdB SurvivalTM 2 T1R competent cells (Life Technologies) were used for the propaga-
tion of any plasmids containing a gateway cassette.
Saccharomyces cerevisiae BY4742 (genotype MATα , his3Δ 1, leu2Δ 0, lys2Δ 0, ura3Δ 0)24, was used for 
homologous recombination-based construction of plasmids, and was maintained on YPDA plates (10 g L−1 yeast 
extract, 20 g L−1 bactopeptone, 20 g L−1 D-glucose, 15 g L−1 agar) at 28 °C.
Fungal strains and growth conditions. Aspergillus oryzae strain NSAR1 (genotype niaD−, sC−, Δ argB, 
adeA−)25, was used as heterologous host. This strain was maintained at 28 °C on MEA plates with appropriate 
supplements (15 g L−1 malt extract, 1.5 g L−1 arginine, 1.5 g L−1 methionine, 0.1 g L−1 adenine, 2 g L−1 ammonium 
sulphate, 15 g L−1 agar).
Clitopilus passeckerianus strain ATCC 34646 was grown routinely on potato dextrose agar (PDA; Sigma, UK) 
at 25 oC for five days. For isolation of genomic DNA four 1 cm2 plugs of mycelial mat were used to inoculate 100 ml 
of CSO1A media (4 ml/L rape seed oil, 50 g/L glucose, 12.5 g/L yeast extract, 1.0 g/L KH2PO4, 0.5 g/L MgSO4⋅ 
7H2O, 0.7 g/L Ca(N03)2.4H2O, 0.1 g/L NaCl, 0.05 g/L FeSO4⋅ 7H2O; pH 6.2) and grown at 25 oC for two days with 
agitation at 230 rpm. Following growth, the mycelium was collected by filtration through Miracloth (Calbiochem 
Corporation, La Jolla, Calif.), washed with TSE buffer (150 mM NaCl, 100 mM EDTA, 50 mM Tris-HCl pH 8.0), 
and blotted dry. Samples were ground in liquid nitrogen and used for extraction of genomic DNA.
For the preparation of RNA, C. passeckerianus was grown in 50 ml of PVS seed medium (8 g/L rape seed oil, 
35 g/L spray dried corn liquor, 15 g/L glucose, 5 g/L calcium carbonate, pH 5.9) for three to five days at 25 oC with 
agitation at 230 rpm. Two ml of the resulting seed media was used to inoculate production or non-production 
media. Production media (CGC) contained 50 g/L glucose, 5 g/L spray dried corn steep liquor and 2 g/L cal-
cium carbonate, pH 6.5. Non-production media (MM) contained 50 mg/L adenine sulphate, 2 g/L L-asparagine, 
25 ml/L of stock A [40 g/L KH2PO4, 90 g/L Na2HPO4, 11.6 g/L Na2SO4, 20 g/L Di-Ammonium tartrate], 1 ml/L of 
stock B [40 mg/L Thiamine], 10 ml/L of stock solution C [25 g/L MgSO4] and 10 g/L glucose, added after auto-
claving, pH 6.5.
Cultures were harvested as described above for DNA extraction and stored at − 80 oC for the preparation of 
RNAs. Stock cultures of C. passeckerianus were maintained on potato dextrose agar at 4 oC or as agar plugs in 20% 
glycerol at − 80 oC.
Nucleic acid isolation. Genomic DNA was isolated from C. passeckerianus mycelia by the method of 
Porebski et al.26. Plasmid and lambda DNA were isolated using Qiagen (Qiagen Ltd, UK) kits. Total RNA was 
isolated using the RNA plant mini kit (Qiagen).
Southern and Northern Blots. For Southern blots, genomic DNA was digested to completion overnight 
with a suitable range of restriction enzymes (New England Biolabs), and separated by agarose gel electrophoresis. 
For Northern blots total RNA (10 μ g) was separated on a 1.2% formaldehyde agarose gel. Genomic DNA digests 
and total RNA were transferred to positively charged nylon membrane (Amersham Life Science) using a vacuum 
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blotter (Bio-rad, UK). Transferred RNA was fixed to membranes by UVP CL-1000 UV cross-linker (Genetic 
Research Instrumentation Ltd, Essex, England). Filters were probed with [α -32P] (3,000 Ci/mmol; Amersham, 
Buckinghamshire, United Kingdom). The labelling of DNAs was performed using Ready-To-Go™ DNA 
Labelling Beads (Amersham Pharmacia Biotech). Unincorporated [α -32P]dCTP was removed using ProbeQuant 
G-50 microspin columns (Amersham Pharmacia Biotech). Hybridization with 32P-labelled probes were carried 
out at 65 oC overnight in Church Buffer (1% BSA, 1 mM EDTA, 0.5 M NaPO4 pH 7.2, 7% SDS). The membranes 
were rinsed in 2 x SSC (20 x SSC per L: 175.3 g NaCl, 88.2 g sodium citrate) at room temperature, followed by a 
20 min wash at 65 oC in 2 x SSC and then a wash in 0.5 x SSC at 65 oC for 20 min. Damp filters were placed on 
Kodak X-Omat AR autoradioagraphy film (Sigma) and allowed to expose for the desired time with intensification 
at − 80 oC to detect hybridization signals.
Degenerate PCR. PCR products amplified with GoTaq DNA polymerase (Promega) were purified with 
Wizard SV Gel (Promega) and PCR Clean-Up System (Promega). These products were routinely cloned into 
pGEM-T easy (Promega) and transformed into E. coli JM109. PCRs were carried out in a final volume of 20 μ l 
containing 1 × Green Go-Taq PCR buffer (Promega), 0.4 mM of each primer, 100 μ M of dNTPs, 2.5 mM MgCl2 
and 1U of Go-Taq DNA polymerase (Promega) and 5 ng of DNA. Reaction conditions for PCR amplification 
consisted of an initial denaturation step at 94 oC for 2 min followed by 30 cycles of: denaturation at 94 oC for 
30 sec, annealing at 50–65 oC for 30 sec and extension at 72 oC for 1 min per kb, with a final extension of 10 min 
at 72 oC. Reactions were carried out in a MJ Research PTC 200 Thermal Cycler (MJ Research, Watertown, MA). 
Degenerate primers fdsf2A and fdsr4 were designed by using conserved sequences identified from an align-
ment of Cryptococcus neoformans var. neoformans JEC21(AAW43830), Lactarius chrysorrheus (BAD15361) and 
Ustilago maydis 521 (XP_757593) and used to amplify a region of Cp-fds gene. To generate a ggs PCR product, 
degenerate primers pair ggs27 and ggs29, originally designed by Zhang et al.27 were used.
Real-Time PCR. Maxima SYBR Green/ROX qPCR Master Mix (Fermentas) was used for all reactions 
(Maxima SYBR Green/ROX qPCR Master Mix: 12.5 μ l, Forward primer: 0.3 μ M, Reverse primer: 0.3 μ M, 
Template cDNA: 25–50 ng, Water to 25 μ l). Reaction conditions were 10 minutes at 95 °C followed by 40 x [95 °C 
for 15 secs, 60 °C for 30 secs, 72 °C for 30 secs]. This was followed by one cycle of 95 °C for 1 min, 60 °C for 30 secs 
and 95 °C for 30 secs to calculate the disassociation curves for each reaction. This was used to confirm that the 
desired amplified product is being detected rather than primer dimers, contamination or misannealed primer 
product. All reactions were carried out using the Mx3005PTM qPCR instrument (Stratagene).
To analyse the results MX-PRO software, which is part of the Mx3005PTM qPCR system, was used. The 
threshold fluorescence was set using the amplification-based algorithm according to the software manufacturer’s 
instructions. The Ct values for each reaction were normalised using β -tubulin as the reference gene. Samples 
were then compared to a calibrator sample (either wild-type or non-production) to gain relative quantification 
of transcript levels.
Construction and screening of a C. passeckerianus genomic library. Fifty micrograms of DNA 
were partially digested with Sau3AI to generate the maximum yield of fragments in the size range 9–23 kb. The 
DNA was then size-fractionated and cloned in Bam HI-linearized vector Lambda GEM-11 (Promega) following 
the vector’s instruction manual. In-vitro packaging was performed using the Packagene Lambda DNA System 
(Promega). Propagation and amplification of the genomic library were performed by infection of E. coli KW251. 
Aliquots of the amplified library were stored in 7% DMSO at − 80 oC. The library was screened by plaque hybrid-
ization with C. passeckerianus ggs and fds probes using standard methods28. To confirm number and position 
of introns in gene sequences, 3′ RACE (Rapid Amplification of cDNA Ends) was performed using the Ambion 
FirstChoice RLM RACE kit.
DNA sequencing and Bioinformatics. Sequencing reactions, in both directions, were carried out by 
GlaxoSmithKline (Harlow, United Kingdom) and Agowa (Berlin, Germany). Sequence data was assembled into 
contigs using Sequencher, version 4.7 (Gene Codes). Database similarity searches were performed using the 
National Centre for Biotechnological Information (NCBI) online program BLAST (http://www.ncbi.nlm.nih.gov/
BLAST)29. The PROSITE database was used to identify motifs and signature sequences in the deduced protein 
sequences with homology to reported proteins (http://www.expasy.ch/tools/scanprosite/)30. Sequence data were 
aligned using the ClustalW program (http://www.ebi.ac.uk/clustalw/)31. DNA and protein sequences were ana-
lysed using the Sequence Manipulation website (http://www.ualberta.ca/~stothard/javascript/)32.
Construction of C. passeckerianus plasmids. Vectors with the selectable marker genes hph (hygromycin 
resistance) and cbx (carboxin resistance) were constructed through yeast-based homologous recombination33. 
The cbx cassettes were amplified from pCbx004 and pCbxi00412 using chimeric primers yeast_AgaricusgpdII_
promf and yeast_AspergillustrpC_termr (Supplementary Table 1), then individually recombined into a 5.8 kb 
XbaI-HindIII fragment of yeast shuttle vector pYES2 (Invitrogen, UK), along with the 1.9 kb fragment of hph 
cassette, which was amplified from pPHT1 by using chimeric primers yeast_coprinustub_promf and yeast_copri-
nustub_termr (Supplementary Table 1). This resulted in the plasmids pYES-hph-cbxgene and pYES-hph-icbx 
respectively (Supplementary Figure 6A). The plasmids are identical except the 64 bp intron-exon region of A. 
bisporus gpdII gene in pYES-hph-icbx. These plasmids were used as bench plasmids to replace either selectable 
marker with genes of interest and transform C. passeckerianus.
To produce Pl-cyc antisense silencing cassette, the coding regions of Pl-cyc was amplified in their entirety with 
suitable primer tails to allow recombination into a XhoI and BamHI fragment of pYES-hph-cbxgene, placing the 
gene in the antisense orientation under the control of the A. bisporus gpdII promoter.
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To produce Pl-cyc antisense silencing cassette, the coding regions of Pl-ggs was amplified in their entirety 
with suitable primer tails to allow ligation into a NcoI and BamHI fragment of pCbx00412, placing the gene in the 
antisense orientation under the control of the A. bisporus gpdII promoter.
In order to clone the pleuromutilin pathway genes under the control of their native promoter sequences, 
individual coding regions of genes with their promoter sequences were amplified from the lambda clones of a 
genomic library of C. passeckerianus, using corresponding chimeric primers with 30 bp-overlap with the pYES2 
vector sequence (Supplementary Table 1). These were individually recombined into a XhoI and BamHI fragment 
of pYES-hph-cbxgene, resulting in overexpression vectors containing pleuromutilin pathway genes under the 
control of their native promoters and A. nidulans trpC terminator sequences (Supplementary Figure 6B).
To obtain plasmids with the pleuromutilin pathway genes under the control of the A. bisporus gpdII promoter 
and A. nidulans trpC terminator, the coding regions of genes were amplified from the corresponding lambda 
clones of C. passeckerianus genomic library, using respective chimeric primers with 30 bp-overlaps with A. bispo-
rus gpdII promoter and A. nidulans trpC terminator sequence (Supplementary Table 1). For genes Pl-cyc, Pl-p450-
1, Pl-p450-2 and Pl-p450-3 the coding region were individually recombined into a XhoI and BamHI fragment of 
plasmid pYES-hph-cbxgene, resulting in overexpression vectors containing pleuromutilin pathway genes under 
the control of A. bisporus gpdII promoter and A. nidulans trpC terminator sequences (Supplementary Figure 
6C). In order to verify the influence of an intron on gene expression levels, the coding regions were also ampli-
fied using a chimeric forward primer with homology to the 64 bp intron-exon region of A. bisporus gpdII. This 
allowed recombination into pYES-hph-icbxgene, placing the coding regions downstream of a 5′ intron. For genes 
Cp-fds and Pl-ggs, the coding regions were individually ligated into NcoI and BamHI fragments of pcbx004 and 
pcbxi00412.
To clone the entire pleuromutilin gene cluster of 25 kb (consisting of coding regions of nine putative genes: 
Pl-p450-3, Pl-atf, Pl-cyc, Pl-ggs, Pl-p450-1, Pl-p450-2, Pl-sdr, Cp-zbdh and Cp-fbm) under the control of their 
native regulatory sequences, the whole 25 kb cluster sequence was amplified as five 5 kb fragments. Each fragment 
was amplified from the corresponding lambda clones, allowing at least 100 bp-overlaps between adjacent frag-
ments. Fragment 1 was amplified from λ 42, fragment 2 from λ 34, fragment 3 from λ G4, fragments 4 and 5 were 
amplified from λ 5. All 5 fragments were recombined into a XhoI and BamHI fragment of plasmid pYES-hph-cbx 
by yeast-based homologous recombination resulting in pYES-hph-pleurocluster (Supplementary Figure 6D).
PEG-mediated transformation of C. passeckerianus. Recombinant plasmids were transformed into C. 
passeckerianus protoplasts as described by Kilaru et al.12.
Bio-assay to determine the pleuromutilin production levels. To determine the pleuromutilin pro-
duction levels, C. passeckerianus transformants and wild type strain were analysed by bio-assay as described in 
Hartley et al.1. This technique was also employed for initial screening of A. oryzae transformants for antibacterial 
activity. Wild-type A. oryzae and C. passeckerianus were used as negative and positive controls respectively.
Heterologous production of pleuromutilin. Expression vectors for the heterologous expression of pleu-
romutilin were constructed through homologous recombination in yeast following the published procedure33. 
The seven genes were amplified from cDNA using Phusion® High-Fidelity DNA Polymerase with extended prim-
ers (Supplementary Table 1). Three expression vectors, pTYGSargGGSCyc, pTYGSadeP450s and pTYGSbarAT-
FSDR (Fig. 3A), were constructed based on those developed by Pahirulzaman, Williams and Lazarus34 and were 
used to transform A. oryzae NSAR1. Protoplast-mediated transformation of A. oryzae was carried out following 
the published protocol35.
Screening A. oryzae transformants for expression and production. Aspergillus oryzae trans-
formants were analysed for expression of the transgenes and production of new metabolites. Each transformant 
strain was grown in 100 mL of CMP medium (35 g L−1 Czapek-dox liquid, 20 g L−1 maltose, 10 g L−1 peptone) 
at 28 °C for five days prior to proceeding with RNA extraction and RT-PCR for expression analysis. A ten-day 
culture of each transformant grown under the same conditions was subject to extraction in ethyl acetate, concen-
trated in vacuo and dissolved in methanol. The crude extract was analysed by HPLC for detection of new metab-
olites and preparative HPLC was used to purify novel metabolites.
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